Hair Loss & Restoration and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 7 records for MSC in Hair Loss & Restoration: 4 recruiting now, 0 labelled Phase 3 or 4, across 4 countries. Snapshot 2026-08-29.
Why this is studied in Hair Loss & Restoration
Androgenetic alopecia is a hormone-driven miniaturisation of follicles, not follicle death, which is why regenerative approaches are biologically plausible: the target still exists. It is also the one tracked indication where exosome registrations outnumber whole-cell studies, reflecting how quickly aesthetic markets adopt cell-free products.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (androgenetic alopecia x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 7 |
| Interventional studies in the sample | 7 |
| Recruiting right now | 4 |
| Completed | 1 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 4 |
| Median planned enrolment | 59 participants |
| Largest single planned enrolment | 120 participants |
| First / most recent start year | 2018 — 2026 |
How mature is this evidence?
No confirmatory-phase record exists yet; 4 of 7 studies are enrolling, so this is a question being asked rather than one being answered.
Of those, 1 are marked completed and 0 were terminated, withdrawn or suspended — a stop rate of 0%, worth weighing when a clinic quotes 'ongoing research' as reassurance.
| Phase label | Records | Share |
|---|---|---|
| Phase 2 | 4 | 40% |
| Phase 1 | 3 | 30% |
| Not applicable | 3 | 30% |
Median planned enrolment is 59 participants (largest single study: 120). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Country coverage runs to 4, but the distribution has a long tail behind China at about 57% of mentions.
| Country | Studies with a site there |
|---|---|
| China | 4 |
| Pakistan | 1 |
| Indonesia | 1 |
| South Korea | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Among the top lead sponsors, 3 are universities or hospitals and 3 are companies, making this a evenly split area.
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan — 1 record
- Zhang Han — 1 record
- PT. Prodia Stem Cell Indonesia — 1 record
- Fujian Medical University Union Hospital — 1 record
- Shenzhen People's Hospital — 1 record
- Medipost Co Ltd. — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07693244 — Exosome Therapy for Male Androgenetic Alopecia | Phase 2 | Recruiting | 120 | Zhang Han | 2026-04-30 |
| NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients | Phase 1, Phase 2 | Recruiting | 40 | PT. Prodia Stem Cell Indonesia | 2026-01-09 |
| NCT07203599 — A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes | Phase 1, Phase 2 | Recruiting | 59 | Shenzhen People's Hospital | 2025-09-20 |
| NCT07373054 — Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia | n/a | Recruiting | 18 | Fujian Medical University Union Hospital | 2025-11-06 |
| NCT06697080 — Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia | n/a | Active Not Recruiting | 50 | Nanfang Hospital, Southern Medical University | 2024-06-28 |
| NCT06764329 — The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. | Phase 1, Phase 2 | Enrolling By Invitation | 70 | National Institute of Blood and Marrow Transplant (NIBMT), P | 2024-12-25 |
| NCT03676400 — Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia | n/a | Completed | 84 | Medipost Co Ltd. | 2018-10-02 |
What this page does and does not tell you
None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Hair Loss & Restoration are recruiting right now?
4 of 7 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Hair Loss & Restoration?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 7 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Hair Loss & Restoration?
0 of 7 records carry a Phase 3 or Phase 4 label and 1 are marked completed. Registrations run from 2018 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.